AZRX - AzurRx BioPharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
+0.0300 (+1.73%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.7300
Bid1.15 x 1000
Ask3.05 x 1400
Day's Range1.7100 - 1.7700
52 Week Range1.6900 - 4.0800
Avg. Volume102,579
Market Cap29.815M
Beta (3Y Monthly)0.39
PE Ratio (TTM)N/A
EPS (TTM)-0.85
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    AzurRx BioPharma to Acquire Payment Rights to Lead Drug Candidate MS1819-SD from Protea Biosciences Group

    AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced that it is acquiring royalty and milestone obligations to its lead drug candidate MS1819-SD, a recombinant lipase for exocrine pancreatic insufficiency, from Protea Biosciences Group (“Protea”), who initiated Chapter 11 proceedings in December 2017. Following an auction held on November 27, 2018, AzurRx emerged as the successful bidder for contractual rights to milestone and royalty payments under a Stock Purchase and Sale Agreement previously executed by AzurRx and Protea.

  • Zacks Small Cap Research12 days ago

    AZRX: 3Q:18 Financial and Operational Summary

    Highlights for the period and to date include participation in investment conferences, presentation of favorable trial data, acceptance of a new IND and a nod of approval from the Therapeutics Development Network for their cystic fibrosis trial protocol. Financial results for the quarter reflect the interim between the chronic pancreatitis study and the cystic fibrosis study and show an expected dip in cash burn. Research and development expenses were up 21% compared to the prior year period as AzurRx established its R&D function in the United States and recognized related costs, but were down sequentially, representing a break between the CP and CF studies.

  • GlobeNewswire12 days ago

    AzurRx BioPharma to Present at Upcoming Investor Conferences

    BROOKLYN, N.Y., Dec. 04, 2018 -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant.

  • GlobeNewswire2 months ago

    AzurRx BioPharma Announces FDA Acceptance of IND Application for Phase 2 Clinical Trial of MS1819-SD in Patients with Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

    AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that the United States Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the Company’s lead asset, MS1819-SD, in patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF).  The Company further announced that it plans to initiate the multi-center Phase 2 study that was the subject of the IND in the United States and Europe in the fourth quarter of 2018 and expects it to conclude in 2019.

  • Zacks Small Cap Research3 months ago

    AZRX: Final Results from Phase II EPI Trial

    Other endpoints were also positive, including Bristol stool scale, number of daily evacuations and weight of stool, which were consistent with the CFA results. CMO Dr. Pennington was pleased at the high level of statistical significance of the results and announced his expectation that the Phase IIb portion of the trial in cystic fibrosis (CF) will begin later in 2018. This compares to the dose response of just over 16% that was achieved in the Phase 1/2a FLIP110 study.

  • GlobeNewswire3 months ago

    AzurRx BioPharma Announces Positive Outcome with MS1819-SD Showing Statistically Significant Efficacy in a Phase IIa Exocrine Pancreatic Insufficiency Trial in Chronic Pancreatitis

    NEW YORK, Sept. 24, 2018-- AzurRx BioPharma, Inc., a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced, in partnership with Mayoly ...

  • Zacks Small Cap Research4 months ago

    AZRX: Phase 2 Cystic Fibrosis Study to Start

    The company’s most important announcement year to date has been the completion of the Phase 2a trial for MS1819 in late June. Trial results were favorable and provided evidence of safety and efficacy for the Yarrowia lipolytica-derived lipase in exocrine pancreatic insufficiency (EPI). The company also raised $10 million in a public offering underwritten by Oppenheimer.

  • Zacks Small Cap Research5 months ago

    AZRX: AzurRx Announces Completion of Phase 2a MS1819 Trial

    AzurRx BioPharma, Inc. (AZRX) announced the completion of the Phase IIa MS1819-SD trial on June 29, 2018 and expects to provide a formal report presenting the data in the fall of 2018 at an as yet unidentified scientific conference. As a reminder, the trial was a Phase 2a open-label, dose escalation study conducted in France, Australia and New Zealand with the goal of identifying the safety of escalating doses and dose response. It was conduted in conjuntion with Mayoly Spindler Laboratories and launched November 17, 2016.

  • Zacks Small Cap Research7 months ago

    AZRX: AzurRx Raises Capital After Confirming Results

    AzurRx BioPharma, Inc. (AZRX) provided an update regarding its Phase 2a trial for MS1819 for treatment of chronic pancreatic insufficiency (EPI) The April 23rd release identified consistent progress in the Phase 2a trial for MS1819 with respect to patient enrollment, safety and dose response. The trial is targeting 12 – 15 patients and is enrolling in France, Australia and New Zealand. Current screening and enrollment trends are on track for a 1H:18 study completion.

  • Benzinga8 months ago

    Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on April 30) CareDx Inc (NASDAQ: CDNA ) Eleven Biotherapeutics Inc (NASDAQ: ...

  • Zacks Small Cap Research8 months ago

    AZRX: French Sites to Help Achieve 1H:18 Enrollment Goal

    AzurRx BioPharma, Inc. (AZRX) filed their fiscal year 2017 10-K on March 16th providing a financial update on the company’s performance. The filing caps off a year that saw progression of the Phase IIa trial for MS 1819 for treatment of exocrine pancreatic insufficiency (EPI), new patent protection filings and new personnel and board additions. In 2018, the company received approval for a clinical site in France and continued to add new patients.

  • ACCESSWIRE9 months ago

    Stock Market Manager Announces the Hosting of Research Coverage of AzurRx, Biopharma, Inc. (NASDAQ: AZRX) by Trickle Research LLC

    CLEARWATER, FL / ACCESSWIRE / March 2, 2018 / The AzurRx Biopharma, Inc. (NASDAQ: AZRX) research report is available on Stock Market Manager ( ): Research Report Here About AzurRx, Biopharma, ...

  • ACCESSWIRE11 months ago

    SeeThruEquity Initiates Coverage on AzurRx BioPharma, Inc. (NASDAQ CM: AZRX) with a Price Target of $10.00

    NEW YORK, NY / ACCESSWIRE / January 30, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has ...